November marks National Lung Cancer Awareness Month and the Michigan Department of Community Health (MDCH) is proud to participate in the national effort to raise public attention about this disease.
Ads by Google
Genetech Inc and OSI Pharmaceuticals have announced their drug Tarceva is effective in delaying the advance of lung cancer. Tarceva is a target agent that is currently used as a second line treatment for patients with Non-small cell lung cancer (NSCLC) after they have failed chemotherapy. OSI and Genentec said their drug met its main goal in a primary treatment clinical trial as it stopped the spread of advanced NSCLC significantly longer than placebo.
A multi-institution team, funded by the National Human Genome Research Institute (NHGRI) of the National Institutes of Health (NIH), today reported results of the largest effort to date to chart the genetic changes involved in the most common form of lung cancer, lung adenocarcinoma. The findings should help pave the way for more individualized approaches for detecting and treating the nation's leading cause of cancer deaths.
Patients operated on by surgeons who do not routinely remove cancer from the lungs may be at a higher risk for complications, according to a study conducted by researchers at Duke University Medical Center.
"Our study found that hospitals that do higher volumes of these types of surgeries have correspondingly lower mortality rates than those who do fewer of the procedures," said Andrew Shaw, M.D., an anesthesiologist at Duke and lead investigator on the study.
Lung cancer is one of the most common — and deadliest — cancers. Small cell lung cancer makes up about 10 percent to 15 percent of all lung cancers. Because of early metastatic spread, small cell lung cancer has very poor long-term survival with less than 10 percent of patients surviving two years after diagnosis.
Chemotherapy is the most common treatment for small cell lung cancer and many consider drugs containing platinum the most effective agents. However, a new evidence review calls that assumption into question.
Five years ago Vera Morrison of Madison Heights was diagnosed with lung cancer- the No. 1 cause of death among men and women in the United States. After radiation treatments failed, her future didn't look so bright.
But then she was given the option to try a new treatment called lung ablation by Beaumont interventional radiologist Michael Savin, M.D. She agreed to treatment with radiofrequency ablation, or RFA. Since her RFA in May 2006, her cancer has been in remission.
A clinical trial looking at combination of two popular lung cancer drugs Tarceva and Avastin showed that the drugs given together for lung cancer treatment do not increase survival rates.
Tarceva is marketed by Genentech and Avastin by Roche. Both drugs are already widely available in US and Europe as lung cancer treatment. Both drugs belong to a series of drugs under targeted therapies – innovative drugs that are also called ‘smart bombs’ because they are able to differ cancerous cells from healthy ones and kill those affected by the disease.
Today a large, national clinical trial for non-small cell lung cancer was launched to validate whether a biomarker can predict clinical benefit in the treatment of this disease. Biomarkers, which are molecules found in the body that can signal an abnormal process or disease, would identify a target, known as epidermal growth factor receptor (EGFR). This receptor can be increased in some lung cancers due to the presence of extra copies of its coding gene.
While lung cancer in smokers and former smokers is the biggest cancer killer by far, lung cancer in people who have never smoked is - by itself - the sixth biggest cancer killer in the United States.
“Most people are not aware that lung cancer among non-smokers has such an enormous impact,” said Lung Cancer Alliance (LCA) President & CEO Laurie Fenton Ambrose today. The heavy burden of lung cancer in non-smokers contradicts the common belief that lung cancer is a disease that strikes only smokers.
All of us at Lung Cancer Alliance, our Board, our advocates and the patients, families and caregivers we represent, extend our deepest sympathy to the wife and family of Paul Newman.
Mr. Newman was an icon of the American stage and film, loved by audiences around the world. He and his devoted and equally talented wife, Joanne Woodward, changed the lives of people in the United States and around the world through their many philanthropic projects.